NCT03692052View on ClinicalTrials.gov

A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

August 20, 2020

Study Completion Date

September 30, 2030

Conditions
Thalassemia
Interventions
DRUG

AG-348

AG-348 tablet orally BID

Trial Locations (4)

94609

UCSF Benioff Children's Hospital Oakland, Oakland

02114

Massachusetts General Hospital, Boston

M5G 2C4

University Health Network (Toronto General Hospital), Toronto

W12 0HS

Imperial College Healthcare NHS Trust (Hammersmith Hospital), London

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY